Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system

JCI Insight(2022)10.1172/jci.insight.158755Source: DataRank Database

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system is a research paper published in JCI Insight (2022). On theSindex it has a DataRank of 0.612. It has been cited 58 times.

N/A

0.612DataRank · unranked

Scored on demand from live citation data

Open Access58 citations

Download PDF

Cite:

Linked data & code

gen arrayexpress pxd uniprot

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)OA: goldTopics (28)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.612

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (22)

Nathaniel W. Mabe ORCID,Bernhard Englinger ORCID,Kin-Hoe Chow,Sydney M. Moyer ORCID,Smitha Yerrum

Live enrichment

PubMed:36040810 PMC:PMC9675470

National Cancer Institute

Grant: R25 CA174650

National Cancer Institute

Grant: F32 CA243290

Austrian Science Fund

Grant: J-4311

National Cancer Institute

Grant: F32 CA261035

National Institutes of Health

Grant: U01 CA176058

National Institutes of Health

Grant: R03 TR 003343

National Institutes of Health

Grant: R35 CA210030

National Institutes of Health

Grant: P01 CA217959

Swiss National Science Foundation

Grant: 199691

Exploring differentiation therapy through genetic targeting of stem-like cancer cells in pediatric high-grade glioma

NCI NIH HHS

Grant: K99 CA279915

National Institutes of Health

Grant: 5U01CA176058-09

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

National Institutes of Health

Grant: 5F32CA243290-03

Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer

National Institutes of Health

Grant: 1R03TR003343-01

Novel genetic dependencies in VRK2 methylated glioblastoma multiforme

National Institutes of Health

Grant: 1R35CA210030-01

Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer

National Institutes of Health

Grant: 7P01CA217959-04

Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance

National Institutes of Health

Grant: 3F32CA261035-01S1

Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy Response

National Institutes of Health

Grant: 2R25CA174650-06

CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences

goldLicense: cc-by

publisherhttp://insight.jci.org/articles/view/158755/files/pdf

publisherhttps://insight.jci.org/articles/view/158755/files/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9675470

Europe_PMChttps://europepmc.org/articles/PMC9675470

Europe_PMChttps://europepmc.org/articles/PMC9675470?pdf=render

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Nervous SystemHumansVaccinia virusVacciniaGliomaNeuroblastomaIntracellular Signaling Peptides and ProteinsChildProtein Serine-Threonine Kinases

Keywords

CancerMolecular geneticsBrain cancerOncologyRIntracellular Signaling Peptides and ProteinsVaccinia virusGliomaProtein Serine-Threonine KinasesNervous SystemNeuroblastomaVacciniaMedicineHumansChildResearch Article

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589315.v1figshare

Additional file 1 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589315figshare

Additional file 2 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589318.v1figshare

Additional file 2 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589318figshare

Additional file 3 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589321.v1figshare

Additional file 3 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589321figshare

Additional file 4 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589324.v1figshare

Additional file 4 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589324figshare

Additional file 5 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589327.v1figshare

Additional file 5 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589327figshare

Additional file 6 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589330.v1figshare

Additional file 6 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589330figshare

Additional file 7 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589333.v1figshare

Additional file 7 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589333figshare

Additional file 8 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589336.v1figshare

Additional file 8 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589336figshare

Additional file 9 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589339.v1figshare

Additional file 9 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589339figshare

Additional file 10 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589342.v1figshare

Additional file 10 of The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase

10.6084/m9.figshare.26589342figshare

Related Papers (10)

Exploring whole-genome duplicate gene retention with complex genetic interaction analysis

N/A

3.1DataRank · unranked

Science(2020)

co-cited

10.1126/science.aaz5667

Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities

N/A

0.574DataRank · unranked

Cancer Discovery(2020)

co-cited

10.1158/2159-8290.cd-19-1274

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

N/A

6.3DataRank · unranked

Nature(2021)

co-cited

10.1038/s41586-021-04246-z

Retention of duplicated genes in evolution

Trends in Genetics(2021)

co-cited

10.1016/j.tig.2021.06.016

Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome

N/A

3.4DataRank · unranked

Cell Reports(2021)

co-cited

10.1016/j.celrep.2021.109597

Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer

N/A

1.5DataRank · unranked

Cancer Discovery(2021)

co-cited

10.1158/2159-8290.cd-20-1213

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

N/A

0.631DataRank · unranked

Cancer Research(2022)

co-cited

10.1158/0008-5472.can-21-4443

EnsemblCompara GeneTrees: Complete, duplication-aware phylogenetic trees in vertebrates

Top 1%

10.6DataRank

Genome Research(2008)

co-cited

10.1101/gr.073585.107

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

N/A

1.3DataRank · unranked

Nature(2005)

co-cited

10.1038/nature03445

Functional Analysis of Gene Duplications in Saccharomyces cerevisiae

N/A

7.2DataRank · unranked

Genetics(2007)

co-cited

10.1534/genetics.106.064329

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system

FAIR Checklist

DataRank Breakdown

Authors (22)

Funding (17 grants)

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)

Related Papers (10)